Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and lead candidate CBX‑250, a T‑cell engager targeting intracellular tumor antigens via HLA‑presented peptides. CEO Briggs Morrison said proceeds will support completion of the lead Phase I trial and expand the pipeline, including a second nominated program. Crossbow’s technology aims to broaden antibody reach to previously inaccessible intracellular targets by mimicking T‑cell receptor recognition; the financing underscores investor interest in next‑generation cell‑directed immunotherapies and will bankroll IND‑enabling and early clinical activities.